Yes, targeting MHC molecules and their pathways is a promising strategy in cancer therapy. Here are a few approaches:
Checkpoint Inhibitors: Drugs like anti-PD-1 and anti-CTLA-4 antibodies can enhance T cell responses by blocking inhibitory signals. Adoptive T Cell Therapy: T cells are engineered to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) that recognize tumor antigens presented by MHC molecules. Vaccination: Cancer vaccines aim to stimulate the immune system to recognize tumor-associated antigens presented by MHC molecules.
